Alerts will be sent to your verified email
Verify Email
GUJTHEM
Positive for this company
Neutral for this company
Negative for this company
Insufficient data to analyse
Global Trust Bank Limited, a joint sector company, originally producing Erythromycin, was taken over by Pharmaceutical Business Group (India) Ltd. The company later entered collaboration with Yuhan Corporation to produce Rifampicin, becoming India's first to do so.
Guj. Themis Biosyn major competitors are Concord Biotech, Medicamen Biotech, Panacea Biotec, Gufic Biosciences, Sequent Scientific, Zota Health Care, Orchid Pharma.
Market Cap of Guj. Themis Biosyn is ₹3,338 Crs.
While the median market cap of its peers are ₹3,620 Crs.
Guj. Themis Biosyn seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annual Report | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | ||
| Earnings Release | Mar | Sep Dec | ||||||||||||||||
| Investor Presentation | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Jun Dec | ||||||||||||||
| Conference Call | Mar Sep | Sep Dec | Sep | |||||||||||||||
|
Conference Call SummaryCon Call Summary
Powered by Gemini
|
